Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug

Stock Track

04/13

IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.

The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.

Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1197511698"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197511698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197511698?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 18:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197511698","market":"nz","top_or_hot":-1,"title":"Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug","media":"Stock Track","content":"<p>IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.</p><p>The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.</p><p>Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-13 18:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.</p><p>The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.</p><p>Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDYA","symbol_name":"IDEAYA Biosciences","start_time":0,"source_url":"","article_id":"1197511698","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197511698","pubTimestamp":1776076722,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.The oncology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDYA":"IDEAYA Biosciences"},"translate_title":"个股追踪|眼癌药物2/3期试验结果积极IDEAYA Biosciences盘前大涨31.15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1},"content_text":"IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}